Stifel analyst Jonathan Block raised the firm’s price target on Elanco (ELAN) to $17 from $16 and keeps a Buy rating on the shares. Stifel likes Elanco’s setup into 2Q25 results, and the stock remains the firm’s favorite idea within Animal Health, the analyst tells investors in a research note. Stifel expects operating margin to expand for the first time in four years in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco Animal Health Amends Receivables Loan Agreement
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Blair upgrades Elanco to Outperform on improved growth outlook
- Elanco upgraded to Outperform from Market Perform at William Blair
- Elanco Animal Health: Balanced Growth Prospects Amid Competitive Challenges and Innovation Uncertainties